Ciltacabtagene Autoleucel in Multiple Myeloma – Optimizing Sequencing, Safety Management, and Care Team Communication

EP. 1: Where Ciltacabtagene Autoleucel Belongs in Sequencing

BySurbhi Sidana, MD,Doris Hansen, MD,Prerna Mewawalla, MD

August 28th 2026

This opening segment introduces a discussion on ciltacabtagene autoleucel (cilta-cel) in multiple myeloma and frames the questions the program sets out to answer: how chimeric antigen receptor (CAR) T-cell therapy should be sequenced among the available options, and how care can be coordinated across a network spread between referring practices and treating centers.

EP. 2: Individualizing CAR T-Cell Therapy vs Bispecific Antibodies in Relapsed Multiple Myeloma

BySurbhi Sidana, MD,Doris Hansen, MD,Prerna Mewawalla, MD

August 28th 2026

The faculty discuss how to individualize the choice between chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies in relapsed multiple myeloma.

Ciltacabtagene Autoleucel in Multiple Myeloma – Optimizing Sequencing, Safety Management, and Care Team Communication

EP. 1: Where Ciltacabtagene Autoleucel Belongs in Sequencing

EP. 2: Individualizing CAR T-Cell Therapy vs Bispecific Antibodies in Relapsed Multiple Myeloma

Trending on CancerNetwork

How Significant is the Approval of Daraxonrasib in Pancreatic Cancer?

FDA Approves Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer

Where Do CELMoDs Fit With CAR T Cells and Bispecifics in Multiple Myeloma?

Daratumumab Combo Sets New OS Benchmark in Transplant-Ineligible NDMM

Biomarker-Independent ADC Rina-S Advances to Phase 3 in Endometrial Cancer